Random guess and wishful thinking are the best blinding scenarios

Contemporary Clinical Trials Communications

Volumn 3, Issue , 2016, Pages 117-121

  Bang, Heejung ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bias; Blinding; Blinding index; Clinical trial

Indexed keywords

ARTICLE; BLINDING PROCEDURE; CLINICAL TRIAL; CONCEPTUAL FRAMEWORK; MATHEMATICAL MODEL; METHODOLOGY; QUANTITATIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIMULATION; THINKING;

EID: 84968918920     PISSN: 24518654     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.conctc.2016.05.003     Document Type: Article

References (28)

1. C.D. Furberg, and E.Z. Soliman Double-blindness protects scientific validity J. Thromb. Haemost. 6 2008 230 231
2. I. Boutron, C. Estellat, and P. Ravaud A review of blinding in randomized controlled trials found results inconsistent and questionable J. Clin. Epidemiol. 58 2005 1220 1226
3. I. Boutron, L. Guittet, C. Estellat, and et al. Reporting methods of blinding in randomized trials assessing nonpharmacological treatments PLoS Med. 4 2007 e61
4. D. Bhatt, D. Kandzari, W. O'Neill, and et al. A controlled trial of renal denervation for resistant hypertension NEJM 370 15 2014 1393 1401
5. A. Crisp Blinding in pharmaceutical clinical trials: an overview of points to consider Contemp. Clin. Trials 43 2015 155 163
6. A. Hrobjartsson, E. Forfang, M.T. Haahr, and et al. Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding Int. J. Epidemiol. 36 2007 654 663
7. H. Jeong, H. Yim, Y. Cho, and et al. The effect of rigorous study design in the research of autologous bone marrow-derived mononuclear cell transfer in patients with acute myocardial infarction Stem Cell Res. Ther. 4 82 2013
8. C. Baethge, O. Assall, and R. Baldessarini Systematic review of blinding assessment in randomized controlled trials in Schizophrenia and Affective Disorders 2000-2010 Psychother. Psychosom. 82 2013 152 160
9. E. Mathieu, R. Herbert, K. McGeechan, and et al. A theoretical analysis showed that blinding cannot eliminate potential for bias associated with beliefs about allocation in randomized clinical trials J. Clin. Epidemiol. 67 2014 667 671
10. M. Symons, and D. Moore Hazard rate ratio and prospective epidemiological studies J. Clin. Epidemiol. 55 2002 893 899
11. H. Davies, I. Crombie, and M. Tavakoli When can odds ratios mislead? BMJ 316 1998 989 991
12. B. Freed, O. Assall, G. Panagiotakis, and et al. Assessing blinding in trials of psychiatric disorders: a meta-analysis based on blinding index Psychiatry Res. 219 2014 241 247
13. A. Moroz, B. Freed, L. Tiedemann, and et al. Blinding measured: a systematic review of randomized controlled trials of acupuncture Evidence-Based Complement. Altern. Med. 2013 708251
14. J. Park, H. Bang, and I. Canette Blinding in clinical trials, time to do it better Complement. Ther. Med. 16 2008 121 123
15. H. Bang, L. Ni, and C.E. Davis Assessment of blinding in clinical trials Control. Clin. Trials 25 2004 143 156
16. O. Arandjelović A new framework for interpreting the outcomes of imperfectly blinded controlled clinical trials PLoS One 7 12 2012 e48984
17. V. Hertzberg, M. Chimowitz, M. Lynn, and et al. Use of dose modification schedules is effective for blinding trials of warfarin: evidence from the WASID study Clin. Trials 5 1 2008 23 30
18. A. Houweling, S. Shapiro, J. Cohen, and et al. Blinding strategies in the conduct and reporting of a randomized placebo-controlled device trial Clin. Trials 11 2014 547 552
19. J. Kolahi, H. Bang, and J. Park Towards a proposal for assessment of blinding success in clinical trials: up-to-date review Community Dent. Oral Epidemiol. 37 6 2009 477 484
20. H. Bang, S.P. Flaherty, J. Kolahi, and et al. Blinding assessment in clinical trials: a review of statistical methods and a proposal of blinding assessment protocol Clin. Res. Regul. Aff. 27 2 2010 42 51
21. H. Bang, and C. Davis On estimating treatment effects under non-compliance in randomized clinical trials: are intent-to-treat or instrumental variables analyses perfect solutions? Statistics Med. 26 2007 954 964
22. J. Roy Randomized treatment-belief trials Contemp. Clin. Trials 33 2012 172 177
23. Z. Zhang, R. Kotz, C. Wang, and et al. A causal model for joint evaluation of placebo and treatment-specific effects in clinical trials Biometrics 69 2 2013 318 327
24. O. Arandjelović Clinical trial adaptation by matching evidence in complementary patient sub-groups of auxiliary blinding questionnaire responses PLoS One 10 7 2015 e0131524
25. H. Bang, Y.-L. Chiu, J.S. Kaufman, and et al. Bias correction methods for misclassified covariates in the Cox model: comparison of five correction methods by simulation and data analysis J. Stat. Theory Pract. 7 2013 381 400
26. S. Walter, S. Awasthi, and L. Jeyaseelan Pre-trial evaluation of the potential for unblinding in drug trials: a prototype example Contemp. Clin. Trials 26 4 2005 459 468
27. The Coronary Drug Project Research Group Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project NEJM 303 18 1980 1038 1041
28. J. Rees, T. Wade, D. Levy, and et al. Changes in beliefs identify unblinding in randomized controlled trials: a method to meet CONSORT guidelines Contemp. Clin. Trials 26 2005 25 37